Kidney international最新文献

{"title":"Relmapirazin, a new exogenous filtration marker, and more widespread use of measured GFR","authors":"Marcelle Tuttle ,&nbsp;Andrew S. Levey","doi":"10.1016/j.kint.2024.07.019","DOIUrl":"10.1016/j.kint.2024.07.019","url":null,"abstract":"<div><p>Plasma or urinary clearance of exogenous filtration markers is required for assessment of measured glomerular filtration rate. Although multiple methods are available, none is widely used because of their complexity, each has measurement error, and standardization is limited. Recently, a study validated the plasma clearance of a new exogenous filtration marker, relmapirazin, which can be detected by its transdermal fluorescence, potentially simplifying the procedure and increasing access to measured glomerular filtration rate.</p></div>","PeriodicalId":17801,"journal":{"name":"Kidney international","volume":"106 4","pages":"Pages 562-565"},"PeriodicalIF":14.8,"publicationDate":"2024-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0085253824005416/pdfft?md5=e1b2629eafc80d55260a35b7fed83894&pid=1-s2.0-S0085253824005416-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142274731","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Case | Dark dialysate after colonoscopy","authors":"Arrsh Bajaj ,&nbsp;Monica Arora ,&nbsp;Udayan Bhatt","doi":"10.1016/j.kint.2024.06.006","DOIUrl":"10.1016/j.kint.2024.06.006","url":null,"abstract":"","PeriodicalId":17801,"journal":{"name":"Kidney international","volume":"106 4","pages":"Pages 761-762"},"PeriodicalIF":14.8,"publicationDate":"2024-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142274820","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Subscription Information","authors":"","doi":"10.1016/S0085-2538(24)00581-7","DOIUrl":"10.1016/S0085-2538(24)00581-7","url":null,"abstract":"","PeriodicalId":17801,"journal":{"name":"Kidney international","volume":"106 4","pages":"Page A2"},"PeriodicalIF":14.8,"publicationDate":"2024-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142274826","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Estimating glomerular filtration rate in kidney transplant recipients: considerations for selecting equations","authors":"Krishna A. Agarwal ,&nbsp;Ogechi M. Adingwupu ,&nbsp;Hocine Tighiouart ,&nbsp;Shiyuan Miao ,&nbsp;Marc Froissart ,&nbsp;Michael Mauer ,&nbsp;Wei Yang ,&nbsp;Vicente Torres ,&nbsp;Martin de Borst ,&nbsp;Goran Klintmalm ,&nbsp;Emilio D. Poggio ,&nbsp;Peter Rossing ,&nbsp;Ruben Velez ,&nbsp;Anders Grubb ,&nbsp;Andrew D. Rule ,&nbsp;Kamran Shaffi ,&nbsp;Ashtar Chami ,&nbsp;Andrew S. Levey ,&nbsp;Lesley A. Inker","doi":"10.1016/j.kint.2024.07.035","DOIUrl":"10.1016/j.kint.2024.07.035","url":null,"abstract":"","PeriodicalId":17801,"journal":{"name":"Kidney international","volume":"106 5","pages":"Pages 991-995"},"PeriodicalIF":14.8,"publicationDate":"2024-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142174732","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Targeting APRIL in the treatment of glomerular diseases","authors":"Chee Kay Cheung ,&nbsp;Jonathan Barratt ,&nbsp;Richard Lafayette ,&nbsp;Adrian Liew ,&nbsp;Yusuke Suzuki ,&nbsp;Vladimír Tesař ,&nbsp;Hernán Trimarchi ,&nbsp;Muh Geot Wong ,&nbsp;Hong Zhang ,&nbsp;Dana V. Rizk","doi":"10.1016/j.kint.2024.08.012","DOIUrl":"10.1016/j.kint.2024.08.012","url":null,"abstract":"<div><div>A proliferation-inducing ligand (APRIL) is a key member of the tumor necrosis factor superfamily of cytokines and plays a central role in B-cell survival, proliferation, and Ig class switching. Recently, there has been increasing interest in the role of APRIL and the related cytokine B-cell activating factor in several glomerular diseases, because of their importance in the above processes. The therapeutic inhibition of APRIL represents a potentially attractive immunomodulatory approach that may abrogate deleterious host immune responses in autoimmune diseases while leaving other important functions of humoral immunity intact, such as memory B-cell function and responses to vaccination, in contrast to B-cell–depleting strategies. In this review, we describe the physiological roles of APRIL in B-cell development and their relevance to glomerular diseases, and outline emerging clinical trial data studying APRIL inhibition, with a focus on IgA nephropathy where the clinical development of APRIL inhibitors is in its most advanced stage.</div></div>","PeriodicalId":17801,"journal":{"name":"Kidney international","volume":"106 5","pages":"Pages 806-818"},"PeriodicalIF":14.8,"publicationDate":"2024-09-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142055925","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A randomized phase 2b trial examined the effects of the glucagon-like peptide-1 and glucagon receptor agonist cotadutide on kidney outcomes in patients with diabetic kidney disease","authors":"Viknesh Selvarajah ,&nbsp;Darren Robertson ,&nbsp;Lars Hansen ,&nbsp;Lutz Jermutus ,&nbsp;Kirsten Smith ,&nbsp;Angela Coggi ,&nbsp;José Sánchez ,&nbsp;Yi-Ting Chang ,&nbsp;Hongtao Yu ,&nbsp;Joanna Parkinson ,&nbsp;Anis Khan ,&nbsp;H. Sophia Chung ,&nbsp;Sonja Hess ,&nbsp;Richard Dumas ,&nbsp;Tabbatha Duck ,&nbsp;Simran Jolly ,&nbsp;Tom G. Elliott ,&nbsp;John Baker ,&nbsp;Albert Lecube ,&nbsp;Karl-Michael Derwahl ,&nbsp;Hiddo J.L. Heerspink","doi":"10.1016/j.kint.2024.08.023","DOIUrl":"10.1016/j.kint.2024.08.023","url":null,"abstract":"<div><div>Cotadutide is a glucagon-like peptide-1 (GLP-1) and glucagon receptor agonist that may improve kidney function in patients with type 2 diabetes (T2D) and chronic kidney disease (CKD). In this phase 2b study, patients with T2D and CKD (estimated glomerular filtration rate [eGFR] of 20 or more and under 90 mL/min per 1.73 m² and urinary albumin-to-creatinine ratio [UACR] over 50 mg/g) were randomized 1:1:1:1:1 to 26 weeks’ treatment with standard of care plus subcutaneous cotadutide uptitrated to 100, 300, or 600 μg, or placebo daily (double-blind), or the GLP-1 agonist semaglutide 1 mg once weekly (open-label).The co-primary endpoints were absolute and percentage change versus placebo in UACR from baseline to the end of week 14. Among 248 randomized patients, mean age 67.1 years, 19% were female, mean eGFR was 55.3 mL/min per 1.73 m², geometric mean was UACR 205.5 mg/g (coefficient of variation 270.0), and 46.8% were receiving concomitant sodium–glucose co-transporter 2 inhibitors. Cotadutide dose-dependently reduced UACR from baseline to the end of week 14, reaching significance at 300 μg (–43.9% [95% confidence interval −54.7 to −30.6]) and 600 μg (−49.9% [−59.3 to −38.4]) versus placebo; with effects sustained at week 26. Serious adverse events were balanced across arms. Safety and tolerability of cotadutide 600 μg were comparable to semaglutide. Thus, our study shows that in patients with T2D and CKD, cotadutide significantly reduced UACR on top of standard of care with an acceptable tolerability profile, suggesting kidney protective benefits that need confirmation in a larger study.</div></div>","PeriodicalId":17801,"journal":{"name":"Kidney international","volume":"106 6","pages":"Pages 1170-1180"},"PeriodicalIF":14.8,"publicationDate":"2024-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142108748","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Targeted gene therapy for rare genetic kidney diseases","authors":"Veenita Khare ,&nbsp;Stephanie Cherqui","doi":"10.1016/j.kint.2024.07.034","DOIUrl":"10.1016/j.kint.2024.07.034","url":null,"abstract":"<div><div>Chronic kidney disease is one of the leading causes of mortality worldwide because of kidney failure and the associated challenges of its treatment including dialysis and kidney transplantation. About one-third of chronic kidney disease cases are linked to inherited monogenic factors, making them suitable for potential gene therapy interventions. However, the intricate anatomical structure of the kidney poses a challenge, limiting the effectiveness of targeted gene delivery to the renal system. In this review, we explore the progress made in the field of targeted gene therapy approaches and their implications for rare genetic kidney disorders, examining preclinical studies and prospects for clinical application. <em>In vivo</em> gene therapy is most commonly used for kidney-targeted gene delivery and involves administering viral and nonviral vectors through various routes such as systemic, renal vein, and renal arterial injections. Small nucleic acids have also been used in preclinical and clinical studies for treating certain kidney disorders. Unexpectedly, hematopoietic stem and progenitor cells have been used as an <em>ex vivo</em> gene therapy vehicle for kidney gene delivery, highlighting their ability to differentiate into macrophages within the kidney, forming tunneling nanotubes that can deliver genetic material and organelles to adjacent kidney cells, even across the basement membrane to target the proximal tubular cells. As gene therapy technologies continue to advance and our understanding of kidney biology deepens, there is hope for patients with genetic kidney disorders to eventually avoid kidney transplantation.</div></div>","PeriodicalId":17801,"journal":{"name":"Kidney international","volume":"106 6","pages":"Pages 1051-1061"},"PeriodicalIF":14.8,"publicationDate":"2024-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142120162","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cyclin-dependent kinase 4 drives cystic kidney disease in the absence of mTORC1 signaling activity","authors":"Florian Grahammer ,&nbsp;Bernhard Dumoulin ,&nbsp;Ramila E. Gulieva ,&nbsp;Hui Wu ,&nbsp;Yaoxian Xu ,&nbsp;Nurgazy Sulaimanov ,&nbsp;Frederic Arnold ,&nbsp;Lukas Sandner ,&nbsp;Tomke Cordts ,&nbsp;Abhijeet Todkar ,&nbsp;Pierre Moulin ,&nbsp;Wilfried Reichardt ,&nbsp;Victor G. Puelles ,&nbsp;Rafael Kramann ,&nbsp;Benjamin S. Freedman ,&nbsp;Hauke Busch ,&nbsp;Melanie Boerries ,&nbsp;Gerd Walz ,&nbsp;Tobias B. Huber","doi":"10.1016/j.kint.2024.08.021","DOIUrl":"10.1016/j.kint.2024.08.021","url":null,"abstract":"<div><div>Progression of cystic kidney disease has been linked to activation of the mTORC1 signaling pathway. Yet the utility of mTORC1 inhibitors to treat patients with polycystic kidney disease remains controversial despite promising preclinical data. To define the cell intrinsic role of mTORC1 for cyst development, the mTORC1 subunit gene <em>Raptor</em> was selectively inactivated in kidney tubular cells lacking cilia due to simultaneous deletion of the kinesin family member gene <em>Kif3A</em>. In contrast to a rapid onset of cyst formation and kidney failure in mice with defective ciliogenesis, both kidney function, cyst formation discerned by magnetic resonance imaging and overall survival were strikingly improved in mice additionally lacking <em>Raptor</em>. However, these mice eventually succumbed to cystic kidney disease despite mTORC1 inactivation. In-depth transcriptome analysis revealed the rapid activation of other growth-promoting signaling pathways, overriding the effects of mTORC1 deletion and identified cyclin-dependent kinase (CDK) 4 as an alternate driver of cyst growth. Additional inhibition of CDK4-dependent signaling by the CDK4/6 inhibitor Palbociclib markedly slowed disease progression in mice and human organoid models of polycystic kidney disease and potentiated the effects of mTORC1 deletion/inhibition. Our findings indicate that cystic kidneys rapidly adopt bypass mechanisms typically observed in drug resistant cancers. Thus, future clinical trials need to consider combinatorial or sequential therapies to improve therapeutic efficacy in patients with cystic kidney disease.</div></div>","PeriodicalId":17801,"journal":{"name":"Kidney international","volume":"106 5","pages":"Pages 856-869"},"PeriodicalIF":14.8,"publicationDate":"2024-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142108751","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A randomized, open-label, clinical trial examined the effects of canagliflozin on albuminuria and eGFR decline using an individual pre-intervention eGFR slope","authors":"Satoshi Miyamoto ,&nbsp;Hiddo J.L. Heerspink ,&nbsp;Dick de Zeeuw ,&nbsp;Kota Sakamoto ,&nbsp;Michihiro Yoshida ,&nbsp;Masao Toyoda ,&nbsp;Daisuke Suzuki ,&nbsp;Takashi Hatanaka ,&nbsp;Tohru Nakamura ,&nbsp;Shinji Kamei ,&nbsp;Satoshi Murao ,&nbsp;Kazuyuki Hida ,&nbsp;Shinichiro Ando ,&nbsp;Hiroaki Akai ,&nbsp;Yasushi Takahashi ,&nbsp;Munehiro Kitada ,&nbsp;Hisashi Sugano ,&nbsp;Tomokazu Nunoue ,&nbsp;Akihiko Nakamura ,&nbsp;Motofumi Sasaki ,&nbsp;Kenichi Shikata","doi":"10.1016/j.kint.2024.08.019","DOIUrl":"10.1016/j.kint.2024.08.019","url":null,"abstract":"<div><div>Demonstrating drug efficacy in slowing kidney disease progression requires large clinical trials when targeting participants with an early stage of chronic kidney disease (CKD). In this randomized, parallel-group, open-labeled trial (CANPIONE study), we assessed the effect of the sodium-glucose cotransporter 2 (SGLT2) inhibitor canagliflozin using the individual’s change in estimated glomerular filtration rate (eGFR) slope before (pre-intervention slope) and during treatment (chronic slope). We randomly assigned (1:1) participants with type 2 diabetes, urinary albumin-to-creatinine ratio (UACR) of 50 to under 300 mg/g, and an eGFR of at least 45 ml/min/1.73m² to receive canagliflozin or guideline-recommended treatment except for SGLT2 inhibitors (control). The first and second primary outcomes were the geometric mean percentage change from baseline in UACR and the change in eGFR slope, respectively. Of 98 randomized participants, 96 received at least one study treatment. The least-squares mean change from baseline in log-transformed geometric mean UACR was significantly greater in the canagliflozin group than the control group (between group-difference, −30.8% (95% confidence interval −42.6 to −16.8). The between-group difference (canagliflozin group – control group) of change in eGFR slope (chronic – pre-intervention) was 4.4 (1.6 to 7.3) ml/min/1.73 m² per year, which was more pronounced in participants with faster eGFR decline. In summary, canagliflozin reduced albuminuria and the participant-specific natural course of eGFR decline in participants with type 2 diabetes and microalbuminuria. Thus, the CANPIONE study suggests that the within-individual change in eGFR slope may be a novel approach to determine the kidney protective potential of new therapies in early stages of CKD.</div></div>","PeriodicalId":17801,"journal":{"name":"Kidney international","volume":"106 5","pages":"Pages 972-984"},"PeriodicalIF":14.8,"publicationDate":"2024-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142108749","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Myeloperoxidase-ANCA IgG induces different forms of small vessel vasculitis based on type of synergistic immune stimuli","authors":"Peiqi Hu ,&nbsp;Hong Xiao ,&nbsp;Marco A. Alba ,&nbsp;Hannah M. Atkins ,&nbsp;Shenju Gou ,&nbsp;Yanglin Hu ,&nbsp;John C. Gomez ,&nbsp;Corey M. Jania ,&nbsp;Jessica R. Martin ,&nbsp;Thomas E. Morrison ,&nbsp;Stephen L. Tilley ,&nbsp;Mark T. Heise ,&nbsp;Claire M. Doerschuk ,&nbsp;Ronald J. Falk ,&nbsp;J. Charles Jennette","doi":"10.1016/j.kint.2024.08.022","DOIUrl":"10.1016/j.kint.2024.08.022","url":null,"abstract":"<div><div>Anti-neutrophil cytoplasmic autoantibody (ANCA) vasculitis has diverse patterns of injury including microscopic polyangiitis (MPA), granulomatosis with polyangiitis (GPA), and eosinophilic granulomatosis with polyangiitis (EGPA). Necrotizing and crescentic glomerulonephritis (NCGN) occurs in all syndromes and as renal limited vasculitis (RLV). Single-dose intravenous ANCA IgG-specific for mouse myeloperoxidase (MPO) causes RLV in mice. Although multiple mouse models have elucidated ANCA–IgG induced necrotizing and crescentic glomerulonephritis (NCGN), pathogenesis of ANCA-induced granulomatosis and vasculitis outside the kidney has not been clarified. To investigate this, we used intravenous MPO-ANCA IgG in the same strain of mice to induce different patterns of lung disease mirroring patients with granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), and eosinophilic granulomatosis with polyangiitis (EGPA). Repeated intravenous MPO-ANCA IgG induced GPA with NCGN, lung capillaritis, arteritis and granulomatosis. Lung leukocyte phenotypes were evaluated by immunohistochemical image analysis and by flow cytometry. ANCA lung capillaritis and microabscesses began within one day and evolved into granulomas in under seven days. Influenza plus single-dose MPO-ANCA IgG induced MPA with NCGN, lung capillaritis and arteritis, but no granulomatosis. Allergic airway disease caused by house dust mites or ovalbumin plus single-dose intravenous MPO-ANCA IgG induced EGPA with eosinophilic bronchiolitis, NCGN, capillaritis, arteritis, and granulomatosis. Thus, our study shows that the occurrence and pattern of lung lesions are determined by the same ANCA IgG accompanied by different synergistic immune factors.</div></div>","PeriodicalId":17801,"journal":{"name":"Kidney international","volume":"106 5","pages":"Pages 870-886"},"PeriodicalIF":14.8,"publicationDate":"2024-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142108752","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}